2 results
Approved WMOCompleted
CORE PERIODPrimary:* Evaluate the safety and tolerability of up to 24 weeks of AG-348 administration in patients with pyruvate kinase deficiency (PK deficiency).Secondary:* Evaluate the pharmacokinetics (PK) of AG-348 and the metabolite AGI-8702.*…
Approved WMOCompleted
This study aims to evaluate the predictive ability of the muscle fatiguability test to predict recovery in older adults admitted to the department of geriatric medicine. Recovery is defined as length of stay, daily functioning after 3 and 6 months…